Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells

OncoImmunology

Volumn 4, Issue 11, 2015, Pages

  Baleeiro, Renato B ^a   Rietscher, René ^b   Diedrich, Andrea ^c   Czaplewska, Justyna A ^d   Lehr, Claus Michael ^b,e   Scherließ, Regina ^c   Hanefeld, Andrea ^f   Gottschaldt, Michael ^d   Walden, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f MERCK KGAA   (Germany)

Author keywords

cancer; cross presentation; dendritic cells; HER2 neu; nanoparticles; tumor associated antigens; vaccine

Indexed keywords

CATHEPSIN; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEASOME; SERINE; THREONINE; TUMOR ANTIGEN;

ACIDIFICATION; ADAPTIVE IMMUNITY; ARTICLE; BIOSYNTHESIS; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL MATURATION; CELL MIGRATION; CHROMOSOME TRANSLOCATION; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84941787327     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1047585     Document Type: Article

References (51)

1. M.J.Bevan. Minor H antigens introduced on H-2 different stimulating cells cross-react at the cytotoxic T cell level during in vivo priming. J Immunol 1976; 117:2233-2238; PMID:825578
2. + T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535-1544; PMID:11104796; http://dx.doi.org/10.1084/jem.192.11.1535
3. P.Paglia, C.Chiodoni, M.Rodolfo, M.P.Colombo. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-322; PMID:8551239; http://dx.doi.org/10.1084/jem.183.1.317
4. M.C.Nussenzweig, R.M.Steinman, B.Gutchinov, Z.A.Cohn. Dendritic cells are accessory cells for the development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp Med 1980; 152:1070-1084; PMID:6968335; http://dx.doi.org/10.1084/jem.152.4.1070
5. M.L.Albert, B.Sauter, N.Bhardwaj. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-89; PMID:9510252; http://dx.doi.org/10.1038/32183
6. M.Kovacsovics-Bankowski, K.L.Rock. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995; 267:243-6; PMID:7809629; http://dx.doi.org/10.1126/science.7809629
7. J.O.Koopmann, J.Albring, E.Hüter, N.Bulbuc, P.Spee, J.Neefjes, G.J.Hämmerling, F.Momburg. Export of antigenic peptides from the endoplasmic reticulum intersects with retrograde protein translocation through the Sec61p channel. Immunity 2000; 1:117-27; PMID:10933400; http://dx.doi.org/10.1016/S1074-7613(00)00013-3
8. T.Di Pucchio, B.Chatterjee, A.Smed-Sörensen, S.Clayton, A.Palazzo, M.Montes, Y.Xue, I.Mellman, J.Banchereau, J.E.Connolly. Direct proteasome-independent cross-presentation of viral antigen by plasmacytoid dendritic cells on major histocompatibility complex class I. Nat Immunol 2008; 9:551-7; PMID:18376401; http://dx.doi.org/10.1038/ni.1602
9. S.Burgdorf, C.Schölz, A.Kautz, R.Tampé, C.Kurts. Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation. Nat Immunol 2008; 9:558-66; PMID:18376402; http://dx.doi.org/10.1038/ni.1601
10. P.Guermonprez, L.Saveanu, M.Kleijmeer, J.Davoust, P.Van Endert, S.Amigorena. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 2003; 425:397-402; PMID:14508489; http://dx.doi.org/10.1038/nature01911
11. M.Houde, S.Bertholet, E.Gagnon, S.Brunet, G.Goyette, A.Laplante, M.F.Princiotta, P.Thibault, D.Sacks, M.Desjardins. Phagosomes are competent organelles for antigen cross-presentation. Nature 2003; 425:402-6; PMID:14508490; http://dx.doi.org/10.1038/nature01912
12. I.Cebrian, G.Visentin, N.Blanchard, M.Jouve, A.Bobard, C.Moita, J.Enninga, L.F.Moita, S.Amigorena, A.Savina. Sec22b regulates phagosomal maturation and antigen crosspresentation by dendritic cells. Cell 2011; 147:1355-68; PMID:22153078; http://dx.doi.org/10.1016/j.cell.2011.11.021
13. A.Savina, C.Jancic, S.Hugues, P.Guermonprez, P.Vargas, I.C.Moura, A.M.Lennon-Duménil, M.C.Seabra, G.Raposo, S.Amigorena. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell 2006; PMID:16839887 126:205-18. 14; http://dx.doi.org/10.1016/j.cell.2006.05.035
14. C.Jancic, A.Savina, C.Wasmeier, T.Tolmachova, J.El-Benna, P.M.Dang, S.Pascolo, M.A.Gougerot-Pocidalo, G.Raposo, M.C.Seabra. Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol 2007; 9:367-78; PMID:17351642; http://dx.doi.org/10.1038/ncb1552
15. J.F.Fonteneau, D.G.Kavanagh, M.Lirvall, C.Sanders, T.L.Cover, N.Bhardwaj, M.Larsson. Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood 2003; 102:4448-55; PMID:12933572; http://dx.doi.org/10.1182/blood-2003-06-1801
16. A.R.Mantegazza, A.Savina, M.Vermeulen, L.Pérez, J.Geffner, O.Hermine, S.D.Rosenzweig, F.Faure, S.Amigorena. NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood 2008; 112:4712-22; PMID:18682599; http://dx.doi.org/10.1182/blood-2008-01-134791
17. N.C.Robson, T.McAlpine, A.J.Knights, M.Schnurr, A.Shin, W.Chen, E.Maraskovsky, J.Cebon. Processing and cross-presentation of individual HLA-A, -B, or -C epitopes from NY-ESO-1 or an HLA-A epitope for Melan-A differ according to the mode of antigen delivery. Blood 2010; 116:218-25; PMID:20430956; http://dx.doi.org/10.1182/blood-2009-10-249458
18. C.N.Baxevanis, P.A.Sotiropoulou, N.N.Sotiriadou, M.Papamichail. Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy. Cancer Immunol Immunother 2004; 53:166-75; PMID:14685781; http://dx.doi.org/10.1007/s00262-003-0475-7
19. Y.L.Yip, R.L.Ward. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 2002; 50:569-587; PMID:11807621; http://dx.doi.org/10.1007/s002620100226
20. R.Kiessling, W.Z.Wie, F.Herrmann, J.A.Lindencrona, A.Choudhury, K.Kono, B.Seliger. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002; 85:101-44; PMID:12374283; http://dx.doi.org/10.1016/S0065-230X(02)85004-7
21. C.N.Baxevanis, N.N.Sotiriadou, A.D.Gritzapis. Immunogenic HER-2/neu peptides as tumor vaccines. Cancer Immunol Immunother 2006; 55:85-95; PMID:15948002; http://dx.doi.org/10.1007/s00262-005-0692-3
22. + T-cell responses against MHC class I epitopes of the HER-2/neu oncoprotein in patients with epithelial tumors. Cancer Immunol Immunother 2003; 52:771-9; PMID:13680193; http://dx.doi.org/10.1007/s00262-003-0420-9
23. B.Fisk, T.L.Blevins, J.T.Wharton, C.G.Ioannides. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995; 181:2109-17; PMID:7539040; http://dx.doi.org/10.1084/jem.181.6.2109
24. + T cells. J Biol Chem 2009; 284:9184-91; PMID:19193636; http://dx.doi.org/10.1074/jbc.M809456200
25. R.A.Rosalia, A.L.Silva, M.Camps, A.Allam, W.Jiskoot, S.H.van der Burg, F.Ossendorp, J.Oostendorp. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles. Cancer Immunol Immunother 2013; 62:1161-73; PMID:23613147; http://dx.doi.org/10.1007/s00262-013-1411-0
26. O.V.Vieira, R.J.Botelho, S.Grinstein. Phagosome maturation: aging gracefully. Biochem J 2002; 366:689-704; PMID:12061891; http://dx.doi.org/10.1042/BJ20020691
27. B.de Saint-Vis, J.Vincent, S.Vandenabeele, B.Vanbervliet, J.J.Pin, S.Aït-Yahia, S.Patel, M.G.Mattei, J.Banchereau, S.Zurawski et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity 1998; 9:325-36; PMID:9768752; http://dx.doi.org/10.1016/S1074-7613(00)80615-9
28. A.Craiu, M.Gaczynska, T.Akopian, C.F.Gramm, G.Fenteany, A.L.Goldberg, K.L.Rock. Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J Biol Chem 1997; 272:13437-45; PMID:9148969; http://dx.doi.org/10.1074/jbc.272.20.13437
29. D.H.Lee, A.L.Goldberg. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol 1998; 8:397-403; PMID:9789328; http://dx.doi.org/10.1016/S0962-8924(98)01346-4
30. E.Reits, J.Neijssen, C.Herberts, W.Benckhuijsen, L.Janssen, J.W.Drijfhout, J.Neefjes. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity 2004; 20:495-506; PMID:15084277; http://dx.doi.org/10.1016/S1074-7613(04)00074-3
31. B.K.Beattie, G.A.Prentice, A.R.Merrill. Investigation into the catalytic role for the tryptophan residues within domain III ofPseudomonas aeruginosa exotoxin A. Biochemistry 1996; 35:15134-42; PMID:8952460; http://dx.doi.org/10.1021/bi961985t
32. A.W.van Weert, H.J.Geuze, B.Groothuis, W.Stoorvogel. Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes. Eur J Cell Biol 2000; 79:394-9; PMID:10928454; http://dx.doi.org/10.1078/0171-9335-00062
33. H.Li, Y.Li, J.Jiao, H.M.Hu. Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response. Nat Nanotechnol 2011; 6:645-50; PMID:21926980; http://dx.doi.org/10.1038/nnano.2011.153
34. P.Nair-Gupta, J.M.Blander. An updated view of the intracellular mechanisms regulating cross-presentation. Front Immunol. 2013; 4:401; PMID:24319447; http://dx.doi.org/10.3389/fimmu.2013.00401
35. J.Imai, H.Hasegawa, M.Maruya, S.Koyasu, I.Yahara. Exogenous antigens are processed through the endoplasmic reticulum-associated degradation (ERAD) in cross-presentation by dendritic cells. Int Immunol 2005; 17:45-53; PMID:15546887; http://dx.doi.org/10.1093/intimm/dxh184
36. P.G.Needham, J.L.Brodsky. How early studies on secreted and membrane protein quality control gave rise to the ER associated degradation (ERAD) pathway: the early history of ERAD. Biochim Biophys Acta 2013; 1833:2447-57; PMID:23557783; http://dx.doi.org/10.1016/j.bbamcr.2013.03.018
37. J.Ménager, F.Ebstein, R.Oger, P.Hulin, S.Nedellec, E.Duverger, A.Lehmann, P.M.Kloetzel, F.Jotereau, Y.Guilloux. Cross-presentation of synthetic long peptides by human dendritic cells: a process dependent on ERAD component p97/VCP but Not sec61 and/or Derlin-1. PLoS One 2014; 9:e89897; PMID:24587108 http://dx.doi.org/10.1371/journal.pone.0089897
38. O.P.Joffre, E.Segura, A.Savina, S.Amigorena. Cross-presentation by dendritic cells. Nat. Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi.org/10.1038/nri3254
39. E.Firat, L.Saveanu, P.Aichele, P.Staeheli, J.Huai, S.Gaedicke, A.Nil, G.Besin, B.Kanzler, P.van Endert et al. The role of endoplasmic reticulum-associated aminopeptidase 1 in immunity to infection and in cross-presentation. J Immunol 2007; 178:2241-8; PMID:17277129; http://dx.doi.org/10.4049/jimmunol.178.4.2241
40. L.Saveanu, O.Carroll, M.Weimershaus, P.Guermonprez, E.Firat, V.Lindo, F.Greer, J.Davoust, R.Kratzer, S.R.Keller et al. IRAP identifies an endosomal compartment required for MHC class I cross-presentation. Science 2009; 325:213-7; PMID:19498108; http://dx.doi.org/10.1126/science.1172845
41. M.Weimershaus, S.Maschalidi, F.Sepulveda, B.Manoury, P.van Endert, L.Saveanu. Conventional dendritic cells require IRAP-Rab14 endosomes for efficient cross-presentation. J Immunol 2012; 188:1840-6; PMID:22238454; http://dx.doi.org/10.4049/jimmunol.1101504
42. M.Grommé, F.G.Uytdehaag, H.Janssen, J.Calafat, R.S.van Binnendijk, M.J.Kenter, A.Tulp, D.Verwoerd, J.Neefjes. Recycling MHC class I molecules and endosomal peptide loading. Proc Natl Acad Sci USA 1999; 96:10326-31; PMID:10468607; http://dx.doi.org/10.1073/pnas.96.18.10326
43. P.A.MacAry, M.Lindsay, M.A.Scott, J.I.Craig, J.P.Luzio, P.J.Lehner. Mobilization of MHC class I molecules from late endosomes to the cell surface following activation of CD34-derived human Langerhans cells. Proc Natl Acad Sci USA 2001; 98:3982-7; PMID:11274420; http://dx.doi.org/10.1073/pnas.071477498
44. G.Basha, K.Omilusik, A.Chavez-Steenbock, A.T.Reinicke, N.Lack, K.B.Choi, W.A.Jefferies. A CD74-dependent MHC class I endolysosomal cross-presentation pathway. Nat Immunol 2012; 13:237-45; PMID:22306692; http://dx.doi.org/10.1038/ni.2225
45. B.Chatterjee, A.Smed-Sörensen, L.Cohn, C.Chalouni, R.Vandlen, B.C.Lee, J.Widger, T.Keler, L.Delamarre, I.Mellman. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012; 120:2011-20; PMID:22791285; http://dx.doi.org/10.1182/blood-2012-01-402370
46. L.Cohn, B.Chatterjee, F.Esselborn, A.Smed-Sörensen, N.Nakamura, C.Chalouni, B.C.Lee, R.Vandlen, T.Keler, P.Lauer et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med 2013; 210:1049-63; PMID:23569326; http://dx.doi.org/10.1084/jem.20121251
47. + T cell responses with broad antigen specificity. J Immunol 2011; 186:1218-27; PMID:21149605; http://dx.doi.org/10.4049/jimmunol.1000808
48. D.Palliser, E.Guillen, M.Ju, H.N.Eisen. Multiple intracellular routes in the cross-presentation of a soluble protein by murine dendritic cells. J Immunol 2005; 174:1879-87; PMID:15699114; http://dx.doi.org/10.4049/jimmunol.174.4.1879
49. + T cell responses against soluble antigens in vivo. J Exp Med 2005; 202:817-28; PMID:16157687; http://dx.doi.org/10.1084/jem.20051106
50. + T-cell response to soluble ovalbumin is improved by chloroquine treatment in vivo. Clin Vaccine Immunol 2008; 10:1497-504; PMID:18753338; http://dx.doi.org/10.1128/CVI.00166-08
51. G.T.Hermanson. Bioconjugates Techniques. 2nd Edition, Elsevier, 2008, 978-0-12-370-501-3, 620; ISBN-13: 978-0123705013